Rexapin

Quick links to important sections

Rexapin

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rexapin

Property Description
Active Ingredient Olanzapine
Form Tablet, Orally Disintegrating Tablet (ODT), Injection
Pharmacological Class Atypical Antipsychotic Agent
General Purpose Stabilizing thought processes and emotional equilibrium
Origin Synthetic Compound (Thienobenzodiazepine derivative)

Rexapin is the trade name for the active chemical substance Olanzapine, which is a prescription-only synthetic psychopharmaceutical used in the management of thought and mood disturbances. Olanzapine is chemically classified as a thienobenzodiazepine derivative, a compound manufactured to target the central nervous system. As a distinct brand containing a well-established INN, Rexapin maintains the core features of Olanzapine: a single active ingredient formulation offered in various forms for flexibility in treatment protocols.

What Type of Medicine is Olanzapine and What is its Core Mechanism?

Olanzapine is classified as an Atypical Antipsychotic Agent, placing it within the group of Second-Generation Antipsychotics (SGA). Its defining characteristic is its multimodal activity, a feature clinically recognized for providing a broader effect compared to older antipsychotic classes. The mechanism involves balancing the activity of neurotransmitters, specifically dopamine and serotonin, to help stabilize and restore equilibrium in the brain's signaling processes. The scientific consensus confirms that this dual-receptor activity is what provides the stabilizing effect on disorganized signaling associated with certain mental states, and it is typically used for conditions requiring the regulation of severe fluctuations in mood and perception.

Olanzapine Composition and Available Forms

Olanzapine, the therapeutic compound, is manufactured synthetically. The drug is available for administration via both oral and intramuscular routes. The currently available dosage forms include the standard conventional tablet and the rapidly dissolving orally disintegrating tablet (ODT). Furthermore, the formulation is available as a short-acting solution for IM injection (used for acute management) and the extended-release depot injection (used for long-term maintenance therapy).

Regulatory References

  1. NIH StatPearls Drug Monograph

What side effects are possible with Rexapin?

Possible Side Effects and Safety Information

The safety profile of Rexapin (Olanzapine) is officially categorized by regulatory agencies based on the frequency and type of adverse reactions observed. The most frequently documented effects are classified as Very Common (occurring in 1 out of 10 people or more) and include weight gain, somnolence (drowsiness), dizziness, and orthostatic hypotension (a drop in blood pressure upon standing). Common reactions (1 in 100 to less than 1 in 10) include increased appetite, edema, and certain movement disorders such as akathisia and tremor.


Serious Adverse Reactions and Systemic Effects

Official labeling documents specific serious adverse reactions. These include the risk of developing metabolic changes, such as hyperglycemia and significant dyslipidemia (alterations in cholesterol and triglycerides). Rare but critical conditions documented in official sources include Neuroleptic Malignant Syndrome (NMS), a potentially irreversible movement disorder called Tardive Dyskinesia (TD), and the potential for thromboembolic events (blood clots).


Population-Specific Safety Notes

The regulatory profile highlights specific safety considerations for certain patient groups. Olanzapine is associated with an increased risk of death and cerebrovascular events (like stroke) in elderly patients with dementia-related psychosis, and it is not approved for use in this population. Safety notes also state that adolescent patients may experience a higher magnitude of weight gain and lipid changes. Some effects, such as orthostatic hypotension, are more frequently observed during the initial dose titration phase of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information for Rexapin

Overdose Scope

Documented overdose presentations: Signs listed in official labeling include somnolence, slurred speech, agitation, miosis (pinpoint pupils), and tachycardia (fast heart rate). More severe manifestations documented are hypotension, delirium, seizures, and states of unresponsiveness leading to coma.

Physiological systems affected: Documented effects involve the Central Nervous System (CNS), the Cardiovascular System, and the Neuromuscular System, with documented risks to the Respiratory System.

Population-specific overdose notes: Increased sensitivity and the potential for severe outcomes, particularly cardiovascular events, are noted for elderly patients.

Emergency-response statements: Seek immediate medical attention and contact emergency services or a poison control center immediately upon suspected overdose.

When immediate medical help is required: Immediate medical help is required whenever any overdose is suspected or confirmed, especially if severe manifestations such as loss of consciousness, seizures, or respiratory distress are present.

Overdose Classifications (High-Level)

Severity classification: The official profile ranges from moderate presentations to severe or life-threatening outcomes, which include ventricular arrhythmia and respiratory failure.

Regulatory basis: The documented overdose profile is based on clinical reporting and toxicological assessments recognized by regulatory bodies globally.

Overdose-context constraints: No specific antidote is known for olanzapine overdose; management relies solely on symptomatic and supportive treatment and mandated monitoring.

Resulting Overdose Structure

Official overdose statements:

  • Continuous cardiac monitoring is required due to the risk of severe cardiac effects.
  • Management procedures include establishing and maintaining adequate ventilation.
  • Interventions such as gastric lavage and administration of activated charcoal should be considered by medical professionals.

Connection to the overall overdose profile: Regulatory documents define the overdose profile through the explicit listing of specific CNS and cardiovascular manifestations, which necessitate an urgent medical response. The profile mandates that patients or caregivers seek immediate medical attention due to the potential for severe or life-threatening outcomes.

Therapeutic Uses of Rexapin

What Rexapin Treats: Main Uses and Benefits

Rexapin (Olanzapine) is a medication used in situations involving certain distressing symptoms, applied across domains where additional symptomatic support is needed, focusing on symptomatic relief and achieving long-term mental stability. The medication is generally used to help with conditions characterized by periods of heightened symptoms.

The medicine may be part of symptomatic management for a range of conditions, including Schizophrenia, Bipolar I Disorder, and the adjunctive treatment of challenging major depressive disorder cases. It is relevant in clinical settings marked by increased discomfort or tension, where short-term symptomatic assistance is needed.

“It is commonly used to help with symptoms that interfere with daily comfort and supports patients during episodes of heightened discomfort.”

The core benefit is providing support that helps ease the overall symptom burden associated with severe disturbances in thought and mood. It is applied when symptoms create noticeable functional strain, such as hallucinations, delusions, severe agitation, and intense racing thoughts.


Quick Fact: Symptomatic Support for Acute Agitation

Rexapin is commonly used when symptoms intensify, such as severe behavioral agitation in psychiatric crises, where it provides supportive relief when symptoms become temporarily overwhelming.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Rexapin

The eligibility profile for Rexapin (Olanzapine) is strictly defined by regulatory documents, outlining populations that are approved, restricted, or explicitly contraindicated.

Classification Population Status per Regulatory Labeling
Contraindication Elderly Patients Must Not Use: Contraindicated for dementia-related psychosis due to increased mortality risk (FDA Boxed Warning).
Contraindication Hypersensitivity Must Not Use: Contraindicated for individuals with a known allergy to Olanzapine or its excipients.
Age Group Children (<13 years) Not Established: Safety and effectiveness are not established for monotherapy use in patients under 13.
Age Group Adolescents (13-17) Approved: Established for monotherapy and combination therapy, though the EMA does not recommend use under 18 due to lack of long-term data.
Comorbidity Hepatic Impairment Restricted: Patients with moderate hepatic insufficiency should consider a lower starting dose and use with caution.
Comorbidity Cardiovascular Risk Caution: Caution is mandated for patients with cardiovascular disease or conditions that may lead to hypotension.
Physiological State Pregnancy (3rd Trimester) Caution: Neonates may experience extrapyramidal/withdrawal symptoms, necessitating careful risk-benefit evaluation and monitoring.

Connection to the overall eligibility profile: Regulatory agencies determine eligibility by formally excluding high-risk populations (contraindications), defining approved age ranges, and mandating caution or dose adjustments based on specific pre-existing health conditions or physiological states.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Rexapin (Olanzapine) interacts with certain substances primarily through effects on its metabolism and through additive actions on the central nervous system (CNS), as documented in official prescribing information.

Pharmacokinetic Interactions (Exposure Modification)

Interaction Type Interacting Substance Official Interaction Outcome
Reduced Clearance Fluvoxamine, Ciprofloxacin Increase in Olanzapine plasma concentration (via CYP1A2 inhibition).
Increased Clearance Carbamazepine, Phenytoin Decrease in Olanzapine plasma concentration (via CYP1A2 induction).

The regulatory labeling notes that tobacco smoking acts as a CYP1A2 inducer, leading to reduced circulating Olanzapine concentrations compared to non-smokers. To avoid a reduction in bioavailability, co-administration with Activated Charcoal requires a separation of at least 2 hours.

Pharmacodynamic and Restriction Interactions

Co-administration with other centrally acting drugs or alcohol may potentiate effects like sedation and orthostatic hypotension.

Specific restrictions exist for the intramuscular (IM) formulation; concurrent use of IM Olanzapine and parenteral benzodiazepines is not recommended due to the risk of excessive sedation and cardiorespiratory depression. Furthermore, Olanzapine may antagonize the effects of dopamine agonists.

Mechanism of Action

How Rexapin Works: Biological Mechanisms

Rexapin (olanzapine) acts as a multi-receptor antagonist to modulate signaling activity in central nervous system pathways, primarily by influencing key neurotransmitter pathways.


Dual Modulation of Serotonin and Dopamine Systems

This mechanistic domain centers on the drug's high-affinity blockade of the 5- HT2A serotonin receptor and its effective, but less sustained, antagonism of the D2 dopamine receptor. This unique binding profile alters the dynamic equilibrium between these systems, influencing the trajectory of neural activity within cortical and subcortical brain pathways.


Kinetic Control of D2 Receptor Activity

The drug exhibits a characteristic property of rapidly unbinding from the D2 receptor after interaction. This kinetic action prevents a high, sustained blockade and influences the degree of dopamine receptor occupancy, which affects signaling in motor control pathways.


Broad Receptor Affinity and Off-Target Consequences

Rexapin’s chemical structure necessitates interaction with several non-primary receptors, including the H1 histamine and muscarinic acetylcholine ( M1-5) receptors. Antagonism at these sites modulates systems governing central arousal and autonomic function, producing alterations in autonomic and metabolic signaling pathways.

Dosage and Administration Information

Rexapin (olanzapine) must be used strictly according to the provided instructions. It is available in several forms, including oral tablets, orally disintegrating tablets (ODT), and short-acting or extended-release intramuscular (IM) injections, each with a specific route of administration and dosing schedule.

Oral Administration and Dosing

Oral formulations (tablets and ODTs) are typically taken once daily and may be administered with or without food as absorption is not affected by meals. The standard adult oral dose range is generally 5 mg to 20 mg per day, with initial dosing often starting at 10 mg/day for schizophrenia and recurrence prevention, or 15 mg/day for manic episodes. Dose increases are advised only after appropriate clinical reassessment and should generally occur at intervals of not less than 24 hours.

Specific Handling and Special Populations

  • ODT Handling: The orally disintegrating tablet must not be pushed through the foil. It should be removed with dry hands immediately after opening the blister and placed on the tongue to dissolve quickly.
  • Missed Dose: If an oral dose is missed, it should be taken as soon as it is remembered unless it is almost time for the next dose; a double dose must never be taken.
  • Special Populations: A lower starting dose (5 mg/day) is recommended for patients aged 65 and over, or for those with evidence of renal or moderate hepatic impairment. A lower starting dose may also be considered in adolescents (ages 13-17).

Intramuscular Administration

The short-acting IM injection is intended for intramuscular use only (not intravenous or subcutaneous) and is used for acute situations. The vial must be reconstituted immediately before use with the specified solvent. The maximum dose for the short-acting IM injection is limited to 30 mg/day. The extended-release IM suspension has a separate, long-term dosing schedule and is not interchangeable with the short-acting injection.

Recent Clinical Evidence

Research Evidence / Overview of studies for Rexapin


Evidence for use in Major Depressive Disorder (MDD)

Rexapin was studied for its use in individuals diagnosed with Major Depressive Disorder, a condition marked by functional limitations and fluctuating symptoms. The research examined short-term, placebo-controlled clinical trials, which are commonly used to gather initial research data. These studies included adult patients, often those who were monitored for changes after prior antidepressant medication alone. Researchers monitored changes in symptom severity using formal rating scales, which are standardized tools relevant in evidence describing how symptoms are measured.

Evidence suggests findings describe patterns observed in these short-term studies, typically spanning six to eight weeks. These findings highlight changes measured during the study period, where studies described numerical measurements recorded between the group receiving the study agent and the control group. The magnitude of these measured differences varied across the included trials.


Evidence for use in Generalized Anxiety Disorder (GAD)

Rexapin was evaluated in research exploring short-term symptom changes for Generalized Anxiety Disorder (GAD), which is characterized by fluctuating or episodic manifestations. The existing evidence is drawn primarily from controlled trials where adult outpatients with GAD were monitored over intervals like 8 to 12 weeks. These studies explored outcomes related to physical discomfort and acute changes in anxiety using standardized scales.

Research describes that studies monitored numerical changes in mean anxiety scale scores. Findings describe patterns observed in the studies where some trials reported how symptoms evolved, noting a pattern of reported changes over the defined time intervals. The reported outcomes were based on measurements from small, specific cohorts.


What is still uncertain about Rexapin

Long-term outcomes are not fully established. Follow-up durations were limited in most key trials, restricting how well research describes whether the observed changes continued beyond the initial study window. Comparative evidence is lacking for direct comparisons between this agent and other similar options.

Data for certain patient groups remain insufficient. Few data are available for specific populations, such as children and adolescents, older adults, or women who are pregnant or breastfeeding. Sample sizes were modest in many studies, and evidence quality varies across trials, meaning certainty remains low in certain areas.

Frequently Asked Questions (FAQ)

Common questions about Rexapin (FAQ)

Q: How quickly does Rexapin start working after taking it?

Regulatory studies show that the medication’s concentration in the blood is reached quickly after administration. However, official information indicates that the full therapeutic effect on symptoms may take several weeks of consistent use to be established.


Q: If I miss a dose of Rexapin, what happens?

Regulatory documents include specific guidelines for managing a missed oral dose, noting that a double dose should never be taken. Missing doses can cause the level of medication in the body to fluctuate, which may affect symptom control.


Q: How long can a person continue to take Rexapin?

The controlled clinical trials supporting the maintenance use of the drug typically cover periods of up to one year, particularly for conditions like recurrence prevention. Due to the potential for long-term changes in metabolism and other body systems, ongoing monitoring is described in regulatory information.


Q: Can Rexapin cause changes in weight?

Yes, regulatory documents list weight gain as a very common side effect. This means it is reported to occur in 1 out of 10 people or more who take the medication.


Q: Are changes in sleep patterns a common effect of Rexapin?

Official information indicates that somnolence, which is medically defined as drowsiness or increased sleepiness, is a very common side effect. It is reported to occur in 1 out of 10 people or more.


Q: How does Rexapin interact with alcohol?

Official regulatory information describes potential concerns with co-administration of alcohol. This is because alcohol may enhance the drug's effects on the central nervous system (CNS), leading to increased sedation, dizziness, and impairment of thinking.


Q: What should I do if I experience an allergic reaction to Rexapin?

The official label notes that this medication is contraindicated if signs of hypersensitivity, such as a rash, fever, or swelling, occur. Official safety warnings indicate that if signs of hypersensitivity are suspected, immediate medical evaluation is required.


Q: What is the relationship between Rexapin and blood pressure?

The medication is officially associated with orthostatic hypotension, which is a sudden drop in blood pressure when moving from a sitting or lying position to standing. This effect is more frequently observed during the initial dose titration phase of treatment.


Q: What types of research studies support the use of Rexapin?

Regulatory approval is primarily based on evidence derived from short-term, placebo-controlled, randomized clinical trials. These studies are used to compare the effects of the medication against a non-active agent.


Q: How long do the common side effects of Rexapin typically last?

Common initial side effects, such as drowsiness or dizziness, often lessen as the body adjusts to the medication. However, certain systemic changes like those related to metabolism or weight require ongoing monitoring over the duration of use.


Q: Do certain medical conditions prevent someone from using Rexapin?

Yes, official regulatory documents state that the drug is strictly contraindicated for patients with a known allergy to the ingredients. It is also contraindicated for use in elderly patients who have dementia-related psychosis.


Q: Does Rexapin have known interactions with common over-the-counter pain relievers?

While specific over-the-counter pain relievers may not be individually itemized, official labeling generally warns against combining Rexapin with any other medication that causes central nervous system (CNS) depression, which could include some painkillers.


Q: Should I worry about mixing Rexapin with herbal supplements?

Official patient information generally advises caution with supplements. Regulatory sources specifically cite the potential for metabolic interactions with certain herbal products, such as St. John's Wort.


Q: Are there specific foods or drinks that should be avoided while taking Rexapin?

The oral forms of the medication can be taken with or without food as absorption is not affected by meals. However, regulatory documents specifically advise against co-administration with alcohol.


Q: What kind of monitoring is typically needed when a person is taking Rexapin?

Regulatory labels advise that monitoring for metabolic changes, including blood glucose and lipid profiles, as well as body weight and vital signs, is recommended. This is part of the ongoing clinical management.


Q: If someone is pregnant, is Rexapin generally considered appropriate to use?

Regulatory documents indicate that use during the third trimester of pregnancy carries a risk of extrapyramidal and/or withdrawal symptoms in the newborn. Regulatory information indicates that use during pregnancy necessitates a careful assessment of risks versus potential benefits.


Q: Is Rexapin known to cause memory problems?

Official documents report adverse reactions that include somnolence, dizziness, and impairment of motor skills and the ability to think. These effects, such as confusion or slowed reaction times, may overlap with user concerns about memory.


Q: What happens if I stop taking Rexapin suddenly?

Official regulatory warnings describe that sudden discontinuation of this type of medication may result in acute withdrawal symptoms. This may necessitate a gradual dose reduction under professional supervision, as typically described in labeling.


Q: Are the side effects of Rexapin permanent?

Official safety warnings specifically document the risk of Tardive Dyskinesia (TD), which is described as a potentially irreversible movement disorder. Other common side effects may resolve once the medication is stopped.


Q: Is there a generic version of Rexapin available?

Yes, the active ingredient in Rexapin is olanzapine. Regulatory records confirm that olanzapine is widely available in FDA-approved generic formulations.


Q: Does Rexapin affect one's ability to drive or operate machinery?

Official warnings describe that caution is advised when driving or operating hazardous machinery. This is due to the potential for common side effects like somnolence (drowsiness), dizziness, and impaired judgment.


Q: Are there specific vitamins that interact with Rexapin?

Regulatory patient information generally advises reporting all concomitant use of products, including vitamins and herbal supplements. This allows for a review of potential interactions, although specific vitamin interactions are not typically listed in detail.


Q: Is Rexapin addictive or habit-forming?

Rexapin is not classified as a controlled substance under the regulatory guidelines of major health authorities. It is not associated with the kind of physical dependence typical of habit-forming or addictive substances.


Q: Can Rexapin be taken with antacids?

Official information explicitly requires separation between this medication and activated charcoal (at least 2 hours). While data on non-activated antacids may not be explicitly listed, any co-administration should be reviewed for potential interactions that could affect drug absorption.


Q: What kind of research has been done on the long-term use of Rexapin?

Regulatory documents refer to open-label extension trials that have lasted several years to collect long-term safety and tolerability data. However, the official follow-up duration of the initial, pivotal trials is often limited.


Q: Are there any known interactions between Rexapin and caffeine?

Caffeine is known to influence the activity of the CYP1A2 enzyme, which is responsible for metabolizing olanzapine. Changes in enzyme activity due to caffeine intake could potentially impact the concentration of the drug in the blood.


Q: Does Rexapin require refrigeration?

No, official regulatory labeling specifies that the oral forms of the medication must be stored at controlled room temperature. They must also be protected from light and moisture.


Q: What should be done if a child accidentally takes Rexapin?

In cases of accidental ingestion, especially by a child, official safety guidance indicates that immediate medical attention is necessary, and contacting the local poison control center is recommended.


Q: How does Rexapin compare to placebo in clinical trials?

Clinical trials consistently reported measured differences in symptom scale scores between the olanzapine group and the placebo (sugar pill) group. These findings are used to support the drug's efficacy for its approved uses.


Q: Why are there different strengths or formulations of Rexapin available?

Different strengths and formulations, such as tablets, orally disintegrating tablets (ODTs), and injections, are available to address various clinical needs. This allows for flexibility in the treatment settings and individual patient requirements.

How should Rexapin be stored and disposed of?

Rexapin (olanzapine) must be stored strictly according to regulatory requirements to preserve its stability.

Official Storage Conditions

Component Requirement
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F) [Source 1.2, 4.4].
Protection Protect from light and moisture. Store in a cool, dry place [Source 3.1, 4.4].
Container Keep in the original container, which must be kept tightly closed [Source 3.5]. Orally disintegrating tablets must remain in their blister packs until use [Source 3.1].
Safety The medicine must be kept out of the reach of children [Source 3.5].

Disposal Requirements

Expired or unused Rexapin must be disposed of in accordance with local, regional, and national regulations [Source 2.5]. Regulatory guidance advises against discarding the medicine by flushing it into the surface water or sanitary sewer systems [Source 2.5].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rexapin found in:

A-Z Index: